Mytesi (Crofelemer) Patent Expiration, LOE Window & CMS Spending

Mytesi (Crofelemer) by Napo: FDA Orange Book LOE 2031-10-31, 0 AB generics, $9.2M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNapo
FDA Application & PathwayN202292 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2031-10-31
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$9.2M
2024 Medicare Part D Spend$8.0M
2024 Medicaid Spend$1.2M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel